NCT05083208 2025-12-02
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
Henan Cancer Hospital
Phase 1 Terminated
Clinical Trials
13 trialsNCT06758713 2025-01-06
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
The Third Affiliated Hospital of Southern Medical University
Phase 1 Recruiting
NCT03245021 2024-07-30
1stFLOR
Austin Health
Phase 1 Active not recruiting
NCT06478381 2024-06-27
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
Henan Cancer Hospital
Phase 1 Recruiting
NCT03610061 2024-04-12
RaDD
Austin Health
Phase 1 Completed
NCT06056752 2023-10-24
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Anhui Provincial Hospital
Phase 1 Recruiting
NCT05900089 2023-06-12
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Henan Cancer Hospital
Phase 1 Not yet recruiting
NCT05528887 2022-09-06
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase 1 Recruiting
NCT03881761 2019-03-21
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Henan Cancer Hospital
Phase 1 Unknown
NCT03881774 2019-03-21
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Henan Cancer Hospital
Phase 1 Unknown
NCT03540303 2018-05-30
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Henan Cancer Hospital
Phase 1 Unknown
NCT02924753 2017-12-29
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Phase 1 Unknown
NCT03101709 2017-04-05
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
Henan Cancer Hospital
Phase 1 Unknown